Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: Two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Hagleitner, Melanie M ^a   Coenen, Marieke J H ^a   Patino Garcia, Ana ^b   De Bont, Eveline S J M ^c   Gonzalez Neira, Anna ^d   Vos, Hanneke I ^a   Van Leeuwen, Frank N ^a   Gelderblom, Hans ^e   Hoogerbrugge, Peter M ^a   Guchelaar, Henk Jan ^e   Te Loo, Maroeska W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CISPLATIN; THIOPURINE METHYLTRANSFERASE; ANTINEOPLASTIC AGENT; COMT PROTEIN, HUMAN; METHYLTRANSFERASE;

ARTICLE; COHORT ANALYSIS; COMT GENE; DUTCHMAN; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OTOTOXICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SPANIARD; TPMT GENE; ADOLESCENT; ADULT; BONE NEOPLASMS; CHEMICALLY INDUCED; CHILD; FEMALE; GENETICS; MALE; META ANALYSIS; NETHERLANDS; PRESCHOOL CHILD; SPAIN; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CATECHOL O-METHYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; GENOTYPE; HEARING LOSS; HUMANS; MALE; METHYLTRANSFERASES; NETHERLANDS; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN; YOUNG ADULT;

EID: 84938631671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115869     Document Type: Article

References (21)

1. Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23: 8588-8596.
2. Li Y, Womer RB, Silber JH (2004) Predicting cisplaitn ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40: 2445-2451.
3. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, et al. (2012) Risk Factors for Cisplatin-Associated Ototoxicity in Pediatric Oncology Patients. Pediatr Blood Cancer 59: 144-148.
4. Blakley BW, Gupta AK, Myers SF, Schwan S (1994) Risk factors for ototoxicity due to cisplaitn. Arch Otolaryngol Head Neck surg 120: 541-546.
5. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, et al. (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61: 1393-1402.
6. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, et al. (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41: 1345-1349.
7. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, et al. (2013) Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 94: 243-251.
8. Yang JJ, Lim JY, Huang J, Bass J, Wu J, et al. (2013) The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 94: 252-259.
9. Hagleitner MM, Coenen MJ, Jeuken JW, Flucke U, Schreuder HW, et al. (2011) Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. Pediatr Blood Cancer 56: 35-38.
10. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, et al. (2012) Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30: 2408-2417.
11. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
12. Sörös P, Stanton SG (2012) On Variability and Genes: Inter-individual Differences in Auditory Brain Function. Front Hum Neurosci 6: 150.
13. von Stechow L, Ruiz-Aracama A, van de Water B, Peijnenburg A, Danen E, et al. (2013) Identification of cisplatin-regulated metabolic pathways in pluripotent stem cells. PLoS One 10:
14. Khrunin AV, Khokhrin DV, Moisseev AA, Gorbunova VA, Limborska SA (2014) Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 15: 329-337.
15. van As JW, van den Berg H, van Dalen EC (2014) Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 7: CD009219.
16. Park MS, De Leon M, Devarajan P (2002) Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13: 858-865.
17. García-Berrocal JR, Nevado J, Ramírez-Camacho R, Sanz R, González-García JA, et al. (2007) The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol 152: 1012-1020.
18. Rybak LP, Whitworth CA (2005) Ototoxicity: therapeutic opportunities. Drug Discov Today 10: 1313-1321.
19. Campbell KC, Meech RP, Klemens JJ, Gerberi MT, Dyrstad SS, et al. (2007) Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 226: 92-103.
20. Videhult P, Laurell G, Wallin I, Ehrsson H (2006) Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Exp Biol Med 231: 1638-1645.
21. Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, et al. (2005) Children's Oncology Group. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 104: 841-847.